By Trevor Lowenthal:
There are some innovative, smaller companies out there that have leveraged the increasingly complicated and unpredictable pharmaceutical industry through diversifying their portfolio of assets across...
By Small Pharma Analyst:
Ligand Pharmaceuticals (LGND) has been the subject of 3 extremely negative articles in Seeking Alpha over the past month by the same author, Amvona. Not only is this author short on this stock, he/she predicts the company...
By Gregory M. Lemelson:
Despite a significant downward correction in the share price of Ligand Pharmaceuticals (LGND) since the June 16,2014 publication of its original research report on LGND, Lemelson Capital Management has...
The following is a list of notable articles to help get you through the lunch hour:
Microsoft (MSFT) Announces Increased Storage, Lower Pricing for OneDrive -> Read this!
Roth Capital Comments on New SERM Lasofoxifene Phase 1 Data (LGND) ->...
Shares of Ligand Pharmaceuticals (NASDAQ: LGND) are down again following the results of the Phase III trial of Promacta.
GSK Releases Promacta Phase III Results
In a press release from June 13, GlaxoSmithKline announced the results from the...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Ligand Pharmaceuticals (LGND):